PPTA Statements

[Blood Products Advisory Committee Meeting on December 2, 2014]

The Plasma Protein Therapeutics Association (PPTA) is the international trade association and standards-setting organization for the world’s major producers of plasma-derived and recombinant analog therapies, collectively referred to as plasma protein therapies. Plasma protein therapies are used in the treatment of a number of rare diseases.

During the October, 21 2016, Source Board of Directors meeting, the Board agreed to remove the voluntary deferral for 60 days of donors returning from Ebola virus disease affected areas in the previous 60 days. The deferral was originally implemented on or about October 13, 2014.

Dear PPTA Stakeholders:

I would like to provide a status report on implementation of PPTA’s European Data Program.

As you know, PPTA launched the program in November 2013 starting with the reporting of Recombinant Factor VIII data. We committed as well to soon begin reporting data on a more complete set of plasma protein therapies. Today we are able to honor that commitment. Please click here to access the data.

The Plasma Protein Therapeutics Association (PPTA) remains deeply concerned about the proposal to ban compensated plasma donation in the Province of Ontario, Canada. The proposed legislation, Ontario Bill 178, unfairly targets compensated plasma donation on alleged bases of safety and Canada’s goal of self-sufficiency in regards to the supply of plasma-derived medicinal products.

The Plasma Protein Therapeutics Association released the following statement regarding passage of the H.R. 3590, the Patient Protection and Affordable Care Act:

"PPTA recognizes the historic achievement of President Obama and Congress in providing affordable, quality health care to millions of Americans.

Last week, the President and Congress could not come to an agreement and on March 1, 2013 sequestration, $85 billion in across the board federal spending cuts, went into effect.

Following the meeting of the Blood Commission on November 16, 2011, where the Amrein et al. study of plateletpheresis donors that reported bone mineral density (BMD) losses at one of three skeletal sites was associated with donating platelets1 was discussed, the Plasma Protein Therapeutics Association (PPTA) was asked to respond to the suggestion that Source Plasma donors

Dear PPTA Stakeholders,

PPTA is pleased to announce that, as of today, reporting of data on the U.S. supply of certain plasma protein therapies has resumed.

Statements in the international media have described the events resulting from the retraction by several leading medical journals of a large number of articles describing scientific studies by a German physician, Joachim Boldt. Boldt was dismissed from his position as head of anesthesia in the Klinikum Ludwigshafen in the state of Rheinland-Pfalz in Germany in November 2010, following initial findings by a leading anesthesia journal that a paper describing a clinical study which Boldt published in the journal had been fabricated.

The U.S. Centers for Disease Control (CDC) is warning Floridians, especially Key West residents, of a viral disease, Dengue fever, that is being spread by a mosquito species.